Bionano Genomics (BNGO) Q1 2026 earnings report highlights $6.7M revenue, 49% gross margin, and strategic reimbursement milestones driving growth.

Key Takeaways

• Revenue for Q1 2026 reached $6.7 million, a 4% increase year-over-year, aligning with guidance.
• Adjusted gross margin improved to 49%, up from 46% in Q1 2025, indicating operational efficiencies.
• Significant reimbursement milestone: New CPT codes enhance OGM adoption potential, with a 47% increase in reimbursement rates.
• Total publications on OGM utility in rare diseases surged 56% year-over-year, highlighting growing market acceptance.
• Q2 2026 revenue guidance set between $7.5 million and $7.8 million, representing 12% to 16% growth over Q2 2025.

Financial Performance

Bionano Genomics, Inc. reported a strong financial performance for the first quarter of 2026, with revenue totaling $6.7 million. This figure marks a 4% increase compared to $6.5 million in Q1 2025 and is at the high end of management’s guidance range of $6.5 million to $6.7 million. The company sold 8,178 nano channel array flow cells, reflecting a 17% growth in unit sales year-over-year, despite ongoing supply constraints.

The adjusted gross margin for the quarter reached 49%, a notable improvement from 46% in the previous year, driven by enhanced operational efficiencies. However, operating expenses rose slightly to $9.1 million from $8.5 million in Q1 2025. The company ended the quarter with $24.7 million in cash and cash equivalents, of which $10.3 million was subject to certain restrictions. This cash position is projected to sustain operations into 2027, as Bionano aims for a cash flow breakeven point.

Strategic Initiatives

Bionano is making significant strides in the adoption of Optical Genome Mapping (OGM), bolstered by recent reimbursement developments. In Q1 2026, two CPT codes were established to improve reimbursement for OGM applications in both hematologic malignancies and constitutional genetic disorders. The 47% increase in payment determination for the Category 1 CPT code for OGM and hematologic malignancies now allows labs to receive $1,853.22 per test, up from $1,263.53. Additionally, the new CPT code for constitutional genetic disorders received a final payment determination of $2,663.53.

These codes are expected to facilitate routine adoption of OGM across oncology and clinical genetic research. The company reported an impressive 56% increase in publications on the utility of OGM in rare diseases, with 28 publications released in Q1 2026. This growing body of research supports OGM's application in a diverse range of conditions and reinforces its value in the medical community.

At the recent Bionano Symposium 2026, over 1,250 registrants participated, showcasing the increasing interest in OGM technology. The conference highlighted advancements in laboratory workflows, with discussions on scaling processes to analyze thousands of samples efficiently. This transition from early adoption to broader scale is a critical theme for Bionano’s future.

Future Outlook

Management remains optimistic about the company’s trajectory moving forward. For the full year 2026, Bionano reaffirmed its revenue guidance of $30 million to $33 million, reflecting growth of 5% to 16% over 2025. The guidance includes expectations for Q2 2026, which is forecasted to generate revenue between $7.5 million and $7.8 million, representing 12% to 16% growth compared to Q2 2025.

Looking ahead, the elimination of outstanding senior secured convertible debt is a considerable milestone that simplifies Bionano's financial profile. Management highlighted that while they do not expect to reach cash flow breakeven by the end of 2026, they are taking necessary steps to reduce burn rates by Q4 2027. With a robust pipeline of publications and research supporting OGM’s efficacy, the company is well-positioned to capitalize on emerging opportunities in the market.

In closing, Bionano Genomics, Inc. has demonstrated a solid start to 2026, characterized by revenue growth and strategic milestones that enhance its position in the genomics landscape. The advancements in reimbursement and publication momentum further solidify the company’s path toward broader adoption of its innovative technology.

This analysis is based on public earnings call materials and is not investment advice.